Biopotential acquisition: development of new electrodes with Imem-CNR

Biopotential acquisition: our challenge is at the meeting point between research and development.

One of Henesis main fields of interest is the development of systems able to overcome the limitation of commercial methods and technologies in healthcare. Henesis R&D teams dedicated several efforts in the development of biocompatible, biodegradable, low cost and usable electrodes for long term acquisition.

In the 2021 Henesis in collaboration with IMEM-CNR filed a patent in which outstanding EXG (ECG, EMG, EEG…) electrodes are designed based on proteic and biocompatible materials. Several people with different knowhow are involved in the development of these technologies that combine the main characteristics of protein materials (biocompatibility, biodegradability, low skin irritation) with the main properties of the commercial synthetic electrodes (long term stability, reliability and adhesion).